HOME > BUSINESS
BUSINESS
- Takeda Founding Family Member Presses for Claw-Back Clause
June 13, 2019
- Growth of Japan Pharma Business Counts on Partnership with Foreign Biotechs: IQVIA Director
June 13, 2019
- Rakuten Medical Could File Photoimmunotherapy for Head and Neck Cancer in 2022; COO Says More Indications Eyed
June 12, 2019
- Taiho Sets Up Venture Capital to Spur Innovation in Japan
June 11, 2019
- Novartis’ Xolair Effective in Severe Cedar Pollen Allergy: Japan PIII
June 11, 2019
- JCR to Launch Japan PI/II for Temcell in Neonatal Hypoxic-Ischemic Encephalopathy
June 11, 2019
- Japan Ethical Drug Sales Surge 5.1% in April: Crecon
June 11, 2019
- Japan Ethical Drug Sales Shrivel, but Many Beat Conservative Guidance
June 11, 2019
- Amicus to Enroll PIII Study for Pompe Therapy AT-GAA by Year-End: COO
June 10, 2019
- Napabucasin PIII Colorectal Cancer Trial to Continue: Sumitomo Dainippon
June 10, 2019
- Keytruda Tops Drug Sales Ranking in May: Encise Snapshot
June 10, 2019
- Pfizer Keeps Diverse Portfolio Strategy amid Sluggish Bavencio, Oncology Chief Says I/O Just One Area of Cancer Care
June 10, 2019
- Oral MDS Treatment ASTX727 Equivalent to IV Dacogen in PIII Study: Otsuka
June 10, 2019
- Taiho to Commercialize Otsuka US Subsidiary’s 2 Cancer Drugs in North America
June 10, 2019
- Konica Minolta Joins Hands with Univ. of Tokyo, NCC on Genetic Profiling
June 7, 2019
- Royalties Push Up Profits at 3 Major Makers, Shionogi Sees 40% Operating Margin This Year
June 7, 2019
- Boehringer’s Japan Pharma Sales on Course for Recovery; Jardiance, Spiolto Upbeat
June 7, 2019
- Astellas Ties Up with Microsoft to Develop Tool Using “Mixed Reality” to Improve Medication Adherence
June 7, 2019
- Fujifilm Toyama Chemical’s T-817MA Enters PII to Examine Post-Stroke Rehabilitation Enhancement Effects
June 7, 2019
- Takeda Calls Off PIII Study of Sakigake-Designated Ninlaro for AL Amyloidosis after Failing to Hit Primary Goal
June 7, 2019
ページ
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
